Exebacase is under clinical development by Aurobac Therapeutics and currently in Phase I for Prosthetic Joint infections. According to GlobalData, Phase I drugs for Prosthetic Joint infections have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Exebacase’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Exebacase overview
Exebacase (PlySs2) is under development for the treatment of prosthetic joint infections. It is a bacteriophage lysin administered through intravenous and intraarticular route. It is developed based on pAVEway advanced protein expression technology. It was also under development for bacterial pnemonia, abscesses, meningitis and skin structure infections (SSSI) caused by bacteria and staphylococcus bacteremia, including methicillin-resistant S. aureus (MRSA), endocarditis.
Aurobac Therapeutics overview
Aurobac Therapeutics is a biopharmaceutical company focus on development of precision medicines addressing the medical needs of antimicrobial resistance and infectious diseases. The company is headquartered in Lyon, Auvergne, France.
For a complete picture of Exebacase’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
